Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michelle K Wilson

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2017
Resisting RECIST-Uniformity Versus Clinical ValidityMichelle K Wilson, Michael L Friedlander, Stephanie Lheureux, et al.
Gynecologic Oncology|May 25, 2015
Stage I granulosa cell tumours: A management conundrum? Results of long-term follow upMichelle K Wilson, Peter Fong, Soizick Mesnage, et al.
The New Zealand Medical Journal|July 12, 2019
Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand-INSIGHTYeojeong Jane So, Michael Jameson, Vincent Newton, et al.
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divideMichelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
American Journal of Obstetrics and Gynecology|June 26, 2021
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferencesAinhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
American Journal of Obstetrics and Gynecology|April 28, 2024
Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences: Am J Obstet Gynecol 225 (2021) 658.e1-658.e9/Article 658Ainhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancerBradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)Bradley J Monk, Christine Parkinson, Myong Cheol Lim, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 11, 2017
Resisting RECIST-Uniformity Versus Clinical ValidityMichelle K Wilson, Michael L Friedlander, Stephanie Lheureux, et al.
Gynecologic Oncology|May 25, 2015
Stage I granulosa cell tumours: A management conundrum? Results of long-term follow upMichelle K Wilson, Peter Fong, Soizick Mesnage, et al.
The New Zealand Medical Journal|July 12, 2019
Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand-INSIGHTYeojeong Jane So, Michael Jameson, Vincent Newton, et al.
The Lancet. Oncology|February 2, 2015
Outcomes and endpoints in cancer trials: bridging the divideMichelle K Wilson, Deborah Collyar, Diana T Chingos, et al.
American Journal of Obstetrics and Gynecology|June 26, 2021
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferencesAinhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
American Journal of Obstetrics and Gynecology|April 28, 2024
Corrigendum to Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences: Am J Obstet Gynecol 225 (2021) 658.e1-658.e9/Article 658Ainhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancerBradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)Bradley J Monk, Christine Parkinson, Myong Cheol Lim, et al.
Pageof 2